Pharming Group Capital Markets Day

New York, NY, June 21, 2018

Please join us for Pharming Group's Capital Markets Day on
Thursday, June 21st in New York City

The event will include presentations from Pharming Group NV (PHARM.NA) senior management, as well as leading clinical experts in the current and new indications of interest.

Of note, Professor Marc Riedl, Professor of Medicine at the University of California, San Diego and Clinical Director of the US HAEA Angioedema Center and a world expert on the diagnosis, treatment and etiology of hereditary angioedema, and Professor Gustaaf Dekker, of the school of Obstetrics and Gynaecology at the University of Adelaide and a world expert on the etiology and treatment of pre-eclampsia, will be presenting.

 

New York, NY
Registration: 7:30am ET
Breakfast & Presentations: 8:00am ET

Ends around 10:30am ET

 

For more information or to RSVP, contact Mike Biega at mbiega@troutgroup.com

A live webcast of the meeting will be accessible on Pharming's website on the front page and under the News section at www.pharming.com​

General Agenda

  • Introduction – Dr Sijmen de Vries, Chief Executive Officer
  • HAE therapeutics overview (acute and prophylaxis indications) – Professor Marc Riedl, US HAEA Angioedema Center at UCSD
  • HAE US market overview – Stephen Toor, Pharming US General Manager
  • Building the RUCONEST® franchise– Professor Bruno Giannetti, Chief Operating Officer
  • rhC1INH development for the treatment/prevention of pre-eclampsia – Professor Gustaaf Dekker, University of Adelaide
  • Contrast-induced nephropathy and cardiac protection – Professor Bruno Giannetti
  • Protein replacement therapies in Pompe and Fabry diseases – Professor Bruno Giannetti
  • Pharming’s new commercial potential – Robin Wright, Chief Financial Officer
  • Summary – Dr Sijmen de Vries
Register for Event / Log Back in

Additional menu options can be found in the menu bar on the left or at the top.

Pharming Group NV [PHARM:AS] €460 MM MCap
On­ly prod­uct with fu­ture po­ten­tial to be ap­proved for both pro­phy­laxis and treat­ment of at­tacks of HAE. An­nounced pos­i­tive re­sults from a ph2 study of RU­CON­EST in Con­tract-in­duced Nephro­pa­thy for pa­tients re­ceiv­ing elec­tive coro­nary an­giog­ra­phy with or with­out a per­cu­ta­neous coro­nary in­ter­ven­tion (PCI). [more in­for­ma­tion]

Event Contact

Mike Biega
Solebury Trout